{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T21:47:32Z","timestamp":1777067252496,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T00:00:00Z","timestamp":1465516800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00415-016-8188-y","type":"journal-article","created":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T11:45:51Z","timestamp":1465559151000},"page":"1727-1735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study"],"prefix":"10.1007","volume":"263","author":[{"given":"Pietro","family":"Annovazzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Moiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Patti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Frau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Uccelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Centonze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Perini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Prosperini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fuiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Falcini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Comi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ghezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,10]]},"reference":[{"key":"8188_CR1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u2013189","journal-title":"Neurology"},{"key":"8188_CR2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/B978-0-444-52001-2.00025-X","volume":"122","author":"DM Wingerchuk","year":"2014","unstructured":"Wingerchuk DM, Weinshenker BG (2014) Neuromyelitis optica (Devic\u2019s syndrome). Handb Clin Neurol 122:581\u2013599","journal-title":"Handb Clin Neurol"},{"key":"8188_CR3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","volume":"17","author":"J Sellnera","year":"2010","unstructured":"Sellnera J, Boggild M, Clanet M et al (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17:1019\u20131032","journal-title":"Eur J Neurol"},{"key":"8188_CR4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","volume":"1","author":"DJ Kimbrough","year":"2012","unstructured":"Kimbrough DJ, Fujihara K, Jacob A et al (2012) Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 1:180\u2013187","journal-title":"Mult Scler Relat Disord"},{"key":"8188_CR5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","volume":"5","author":"MD Pescovitz","year":"2006","unstructured":"Pescovitz MD (2006) Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 5:859\u2013866","journal-title":"Am J Transplant"},{"key":"8188_CR6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ (2010) Rituximab: mechanism of action. Semin Haematol 47:115\u2013123","journal-title":"Semin Haematol"},{"key":"8188_CR7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","volume":"24","author":"CF Lucchinetti","year":"2014","unstructured":"Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T (2014) The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol 24:83\u201397","journal-title":"Brain Pathol"},{"key":"8188_CR8","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BA Cree","year":"2005","unstructured":"Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270\u20131272","journal-title":"Neurology"},{"key":"8188_CR9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10072-007-0823-z","volume":"28","author":"M Capobianco","year":"2007","unstructured":"Capobianco M, Malucchi S, di Sapio A et al (2007) Variable responses to rituximab treatment in neuromyelitis optica (Devic\u2019s disease). Neurol Sci 28:209\u2013211","journal-title":"Neurol Sci"},{"key":"8188_CR10","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob A, Weinshenker BG, Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65:1443\u20131448","journal-title":"Arch Neurol"},{"key":"8188_CR11","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","volume":"17","author":"GS Bedi","year":"2011","unstructured":"Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA (2011) Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 17:1225\u20131230","journal-title":"Mult Scler"},{"key":"8188_CR12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/NRL.0b013e31820a9d35","volume":"17","author":"R Bomprezzi","year":"2011","unstructured":"Bomprezzi R, Postevka E, Campagnolo D, Vollmer TL (2011) A review of cases of neuromyelitis optica. Neurologist 17:98\u2013104","journal-title":"Neurologist"},{"key":"8188_CR13","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","volume":"76","author":"HL Pellkofer","year":"2011","unstructured":"Pellkofer HL, Krumbholz M, Berthele A et al (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76:1310\u20131315","journal-title":"Neurology"},{"key":"8188_CR14","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458511432896","volume":"18","author":"BM Greenberg","year":"2012","unstructured":"Greenberg BM, Graves D, Remington G et al (2012) Rituximab dosing and monitoring strategies in neuromyelitis optica: creating strategies for therapeutic success. Mult Scler 18:1022\u20131026","journal-title":"Mult Scler"},{"key":"8188_CR15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","volume":"317","author":"JW Lindsey","year":"2012","unstructured":"Lindsey JW, Meulmester KM, Brod SA, Nelson F, Wolinsky JS (2012) Variable results after rituximab in neuromyelitis optica. J Neurol Sci 317:103\u2013105","journal-title":"J Neurol Sci"},{"key":"8188_CR16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2012.09.024","volume":"324","author":"VH Ip","year":"2013","unstructured":"Ip VH, Lau AY, Au LW et al (2013) Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci 324:38\u201339","journal-title":"J Neurol Sci"},{"key":"8188_CR17","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","volume":"70","author":"SH Kim","year":"2013","unstructured":"Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ (2013) A 5-year follow-up of rituximab treatment in patients with Neuromyelitis Optica spectrum disorder. JAMA Neurol 70:1110\u20131117","journal-title":"JAMA Neurol"},{"key":"8188_CR18","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","volume":"81","author":"CS Yang","year":"2013","unstructured":"Yang CS, Yang L, Li T et al (2013) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81:710\u2013713","journal-title":"Neurology"},{"key":"8188_CR19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71:324\u2013330","journal-title":"JAMA Neurol"},{"key":"8188_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2015.02.012","volume":"351","author":"J Torres","year":"2015","unstructured":"Torres J, Pruitt A, Balcer L, Galetta S, Markowitz C, Dahodwala N (2015) Analysis of the treatment of neuromyelitis optica. J Neurol Sci 351:31\u201335","journal-title":"J Neurol Sci"},{"issue":"4","key":"8188_CR21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/1352458515594042","volume":"22","author":"M Radaelli","year":"2016","unstructured":"Radaelli M, Moiola L, Sangalli F et al. (2016) Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in caucasian patients. Mult Scler 22(4):511\u2013519. doi: 10.1177\/1352458515594042","journal-title":"Mult Scler"},{"issue":"7","key":"8188_CR22","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1177\/1352458515602337","volume":"22","author":"N Collongues","year":"2015","unstructured":"Collongues N, Brassat D, Maillart E, et al. (2015) Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler 22(7):955\u2013959. doi: 10.1177\/1352458515602337","journal-title":"Mult Scler"},{"key":"8188_CR23","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","volume":"262","author":"H Z\u00e8phir","year":"2015","unstructured":"Z\u00e8phir H, Bernard-Valnet R, Lebrun C et al (2015) Rituximab as first-line therapy in Neuromyelitis optica: efficiency and tolerability. J Neurol 262:2329\u20132335","journal-title":"J Neurol"},{"issue":"9","key":"8188_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","volume":"72","author":"SH Kim","year":"2015","unstructured":"Kim SH, Jeong IH, Hyun JW et al. (2015) Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 72(9):989\u2013995. doi: 10.1001\/jamaneurol.2015.1276","journal-title":"JAMA Neurol"},{"key":"8188_CR25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2015","unstructured":"Hauser SL, Waubant E, Arnold DL et al (2015) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676\u2013688","journal-title":"N Engl J Med"},{"key":"8188_CR26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cncr.23144","volume":"112","author":"G Poeta Del","year":"2008","unstructured":"Del Poeta G, Del Principe MI, Buccisano F et al (2008) Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 112:119\u2013128","journal-title":"Cancer"},{"key":"8188_CR27","unstructured":"Miravalle AA, Kinkel R, Langer-Gould A et al. (2009) B Cell depletion and safety of low dose Rituximab in patients with Relapsing Remitting Multiple Sclerosis. Presented at the LXI AAN congress; Seattle, WA"},{"key":"8188_CR28","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33:1444\u20131452","journal-title":"Neurology"},{"key":"8188_CR29","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuck","year":"2006","unstructured":"Wingerchuck DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485\u20131489","journal-title":"Neurology"},{"key":"8188_CR30","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191\u20132194","journal-title":"JAMA"},{"key":"8188_CR31","first-page":"918","volume":"84","author":"J Kitley","year":"2013","unstructured":"Kitley J, Elsone L, George J et al (2013) Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. JNNP 84:918\u2013921","journal-title":"JNNP"},{"key":"8188_CR32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-2377-14-51","volume":"14","author":"RS Ramanathan","year":"2014","unstructured":"Ramanathan RS, Malhotra K, Scott T (2014) Treatment of neuromyelitis optica\/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurol 14:51","journal-title":"BMC Neurol"},{"key":"8188_CR33","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3324\/haematol.11709","volume":"92","author":"D Provan","year":"2007","unstructured":"Provan D, Butler T, Evangelista ML et al (2007) Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 92:1695\u20131698","journal-title":"Haematologica"},{"key":"8188_CR34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","volume":"82","author":"S Blum","year":"2010","unstructured":"Blum S, Gillis D, Brown H et al (2010) Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry 82:659\u2013663","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8188_CR35","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/imj.12207","volume":"43","author":"J Chay","year":"2013","unstructured":"Chay J, Donovan P, Cummins L, Kubler P, Pillans P (2013) Experience with low-dose rituximab in off-label indications at two tertiary hospitals. Intern Med J 43:871\u2013882","journal-title":"Intern Med J"},{"key":"8188_CR36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/acr.22116","volume":"66","author":"M Bredemeier","year":"2014","unstructured":"Bredemeier M, de Oliveira FK, Rocha CM (2014) Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 66:228\u2013235","journal-title":"Arthritis Care Res"},{"key":"8188_CR37","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s10067-015-2977-z","volume":"34","author":"M Bredemeier","year":"2015","unstructured":"Bredemeier M, Campos GG, de Oliveira FK (2015) Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis. Clin Rheumatol 34:1801\u20131805","journal-title":"Clin Rheumatol"},{"key":"8188_CR38","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF Vollenhoven Van","year":"2013","unstructured":"Van Vollenhoven RF, Emery P, Bingham CO 3rd et al (2013) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72:1496\u20131502","journal-title":"Ann Rheum Dis"},{"key":"8188_CR39","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1631\/jzus.B1200057","volume":"13","author":"L Lan","year":"2012","unstructured":"Lan L, Han F, Chen JH (2012) Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. J Zhejiang Univ Sci B 13:731\u2013744","journal-title":"J Zhejiang Univ Sci B"},{"key":"8188_CR40","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","volume":"64","author":"ES Molloy","year":"2012","unstructured":"Molloy ES, Calabrese LH (2012) Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 64:3043\u20133051","journal-title":"Arthritis Rheum"},{"key":"8188_CR41","doi-asserted-by":"publisher","first-page":"174720","DOI":"10.1155\/2015\/174720","volume":"2015","author":"M Etemadifar","year":"2015","unstructured":"Etemadifar M, Nasr Z, Khalili B, Taherioun M, Vosoughi R (2015) Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis. Mult Scler Int 2015:174720. doi: 10.1155\/2015\/174720","journal-title":"Mult Scler Int"},{"key":"8188_CR42","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 53:1107\u20131114","journal-title":"Neurology"},{"key":"8188_CR43","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1212\/WNL.0000000000001520","volume":"84","author":"BG Weinshenker","year":"2015","unstructured":"Weinshenker BG, Barron G, Behne JM et al (2015) Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology 84:1805\u20131815","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-016-8188-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-016-8188-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-016-8188-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T16:06:11Z","timestamp":1498320371000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-016-8188-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,10]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["8188"],"URL":"https:\/\/doi.org\/10.1007\/s00415-016-8188-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,10]]}}}